EMBO Molecular Medicine

EMBO Molecular Medicine is a fully open access journal published by EMBO Press, part of the EMBO organisation and hosted on Springer Nature, founded in 2009 to publish highly selective translational research that connects molecular mechanisms with clinical medicine, with a 2025 Journal Impact Factor of 7.9 and a first-quartile rank of 25 among 191 research and experimental medicine journals《EMBO 分子医学》（EMBO Molecular Medicine）是由（EMBO Press）出版的完全开放获取期刊，属（EMBO）体系并托管于（Springer Nature），2009 年创刊，发表把分子机制与临床医学相衔接的高选择性转化研究，2025 年影响因子为 7.9，在 191 种研究与实验医学类期刊中列第 25 位，居第一四分位。

Scope

• The journal advances translational and biomedical research discoveries, preferring work that moves a mechanism toward clinical relevance or a clinical observation toward mechanism该刊推进转化与生物医学研究发现，偏好把机制推向临床相关性、或把临床观察推向机制解析的工作。
• Human disease mechanisms across cancer, immunology, infectious disease, neuroscience, metabolism and cardiovascular biology are represented in its pages肿瘤、免疫、感染性疾病、神经科学、代谢与心血管生物学中的人类疾病机制均见于其版面。
• Preclinical models are considered when they carry clear therapeutic implications rather than descriptive value alone临床前模型须具备明确治疗意义，而非仅有描述价值，方予考虑。
• Clinical and patient-oriented studies, including early-phase trials with mechanistic endpoints, fall within scope临床与以患者为导向的研究（含带机制终点的早期试验）属于收稿范围。
• Genomic, proteomic, metabolomic and imaging approaches that illuminate disease biology are welcomed, as are systems-level analyses阐明疾病生物学的基因组、蛋白质组、代谢组与影像学方法，以及系统层面分析，均受欢迎。
• Published articles carry plain-language summaries so that non-specialist readers can grasp the main findings and their medical implications发表文章附通俗摘要，使非专业读者也能把握主要发现及其医学意义。
• Research articles, reviews and reports are published, with commentary and policy content appearing in the wider EMBO Press portfolio刊载研究论文、综述与报告，评论与政策类内容则在（EMBO Press）更大范围内发表。

History

• EMBO Molecular Medicine was launched in 2009 and was described by its publisher as the first fully open access journal dedicated to highly selective translational research该刊 2009 年创刊，出版方称其为第一种专注于高选择性转化研究的完全开放获取期刊。
• From its launch until December 2013 it was published by Wiley-Blackwell together with EMBO, after which EMBO Press took over the publishing operation自创刊至 2013 年 12 月，该刊由（Wiley-Blackwell）与（EMBO）合作出版，此后出版业务转由（EMBO Press）承担。
• The journal now appears continuously, and EMBO Press journals are hosted on the Springer Nature platform following the migration of its sites该刊现以连续出版方式出刊，随着站点迁移，（EMBO Press）各刊托管于（Springer Nature）平台。
• Its Journal Impact Factor stood at 12.137 in 2021 and 14.26 in 2022 before falling to 8.3 in 2024 and 7.9 in the 2025 JCR release其影响因子 2021 年为 12.137、2022 年为 14.26，2024 年降至 8.3，2025 年版为 7.9。
• The publisher notes that the 2025 impact factor was miscalculated through inclusion of non-citable items and reports a corrected value of 8.3, while cautioning against impact factor use as a DORA signatory出版方说明 2025 年影响因子因计入非可引文献而有误，公布更正值为 8.3，并作为（DORA）签署方提醒不宜以影响因子评价研究。

Editors

• The Chief Editor is Philippe Sansonetti, professor at the College de France and a microbiologist known for work on Shigella pathogenesis现任主编为（College de France）教授 Philippe Sansonetti，以志贺菌致病机制研究著称。
• Manuscripts are handled by a team of professional scientific editors rather than by an external academic board alone, a model EMBO Press applies across its journals稿件由专业科学编辑团队处理，而非仅依赖外部学术编委，（EMBO Press）各刊均采用这一模式。
• Authors may request consultative transfers between EMBO Press journals and with Nature partner journals, providing an efficient path after rejection作者可申请在（EMBO Press）各刊之间以及与（Nature）合作期刊之间协商转投，被拒后仍有高效发表路径。
• Peer review is transparent and consultative, with pre-decision discussion between editors and authors and revision discussions before final decisions评审透明且具协商性，编辑与作者在决定前沟通，最终决定前还可就修改进行讨论。
• The journal offers scooping protection from preprint posting, data-integrity curation services, and reports a median of two days from submission to first decision该刊提供预印本发布后的优先权保护与数据完整性整备服务，并公布投稿至首次决定的中位时间为 2 天。